Independent company use-case study · taste and nutrition

Kerry GroupFive process decisions

Choose one use case. Add authorised plant data. Test capacity, cost and constraints.
Acatian flowsheet workspace for a Kerry Group process decision
Assumptions, equipment, capacity, cost and evidence on one model basis.

Decision brief

One question. One model.

Decision

Advance one formulation, ingredient route, scale or campaign option only after product requirements, material recovery, equipment fit, finite resources, economics, environmental inventory and evidence maturity remain consistent.

System boundary

Authorised raw materials or fermentation feed through conversion, cultivation or blending, separation, concentration, drying, formulation and packing, including cleaning, utilities, quality holds, waste and accepted product.

Five practical use cases

Five places to start.

Evaluation scopes for Kerry Group—not claims of current software use.
01

Compare formulation and ingredient routes

Connect authorised taste, nutrition and functional targets to fermentation-derived, enzymatic, extracted or blended alternatives on one material, quality, time and uncertainty basis.

02

Screen biotechnology scale-up and equipment fit

Translate laboratory or pilot evidence into mixing, oxygen-transfer, heat-removal and downstream-load envelopes, then test requirements against approved vessels, separators, concentrators and utilities.

03

Schedule multi-product ingredient campaigns

Sequence eligible reactors or fermenters, recovery equipment, blenders, dryers, cleaning, laboratories and release holds without representing Kerry's actual recipes, sites, capacity or commitments.

04

Compare route economics and lifecycle inventory

Evaluate alternatives across accepted yield, raw materials, energy, water, waste, packaging, capital and operating cost under one declared functional unit, system boundary and uncertainty range.

05

Govern formulation and process-change evidence

Link requirements, source data, formulation and process versions, experiments, risks, specifications and acceptance criteria while keeping model review separate from formal safety, quality or regulatory approval.

Action pack

Inputs in. Decisions out.

Minimum inputs
  • Taste, nutrition, functionality, safety and quality requirements
  • Formulation, reaction, fermentation, recovery and stability evidence
  • Equipment eligibility, scale rules, hold times and site limits
  • Materials, utilities, waste, cost and lifecycle factors
Required outputs
  • Formulation and ingredient-route comparison
  • Biotechnology scale-up and equipment-fit evidence map
  • Finite campaign schedule and accepted-output range
  • TEA/LCA screen and governed change register
First three steps
  • Select one authorised formulation or ingredient decision.
  • Declare product, process and environmental boundaries.
  • Import development, pilot and equipment evidence.

Evidence and limits

Public evidence only.

  1. Kerry Group — Investor FAQOfficial legal context for Kerry Group plc, its Irish registered office and stock-exchange listings.
  2. Kerry Group — Kerry Dairy Ireland transactionOfficial current boundary for Kerry as a pure-play B2B taste and nutrition group after the transaction's first phase.
  3. Kerry Group — 2025 Annual ReportOfficial current group context, including the taste and nutrition focus, biotechnology capabilities, science network and sustainability programme.
  4. Kerry — About usOfficial context for Kerry's portfolio across food, beverage, biotechnology, pharma and proactive health.
  5. Kerry — ManufacturingOfficial process context for fermentation, extraction, reaction, ultrafiltration, blending and spray drying.
  6. Kerry — Industrial fermentationOfficial context for Kerry's own industrial-bioprocessing technologies, expertise and customer services.

Guardrail: No Kerry customer, recipe, formulation, ingredient, process, site, campaign, capacity, taste or nutrition result, cost, environmental result, deployment or digital system is represented. Product safety, quality, sensory, regulatory, investment and release decisions remain within approved Kerry processes.